|Other Names||Kininogen-1, Alpha-2-thiol proteinase inhibitor, Fitzgerald factor, High molecular weight kininogen, HMWK, Williams-Fitzgerald-Flaujeac factor, Kininogen-1 heavy chain, T-kinin, Ile-Ser-Bradykinin, Bradykinin, Kallidin I, Lysyl-bradykinin, Kallidin II, Kininogen-1 light chain, Low molecular weight growth-promoting factor, KNG1, BDK, KNG|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin- induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW- kininogen is in contrast to HMW-kininogen not involved in blood clotting.|
|Cellular Location||Secreted, extracellular space.|
|Tissue Location||Secreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Pyroglutamyl peptidase I (EC 188.8.131.52) catalyzes thehydrolysis of N-terminal pyroglutamyl residues from oligopeptidesand proteins.
Rose, J. Phd, et al. Mol. Med. (2010) In press :Valdivia, A., et al. Regul. Pept. 122(2):79-84(2004)Minderman, H., et al. Clin. Cancer Res. 10(5):1826-1834(2004)Dando, P.M., et al. Protein Expr. Purif. 28(1):111-119(2003)Gil, J., et al. Neuropeptides 35 (5-6), 276-284 (2001) :
If you have any additional inquiries please email technical services at firstname.lastname@example.org.